247 related articles for article (PubMed ID: 33651108)
21. Lack of correlation between the costs of anticancer drugs and clinical benefits in Japan.
Satoh E; Sasaki Y; Ohkuma R; Takahashi T; Kubota Y; Ishida H; Hamada K; Kiuchi Y; Tsunoda T
Cancer Sci; 2018 Dec; 109(12):3896-3901. PubMed ID: 30315613
[TBL] [Abstract][Full Text] [Related]
22. Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non-Small-Cell Lung Cancer.
Lakdawalla DN; Chou JW; Linthicum MT; MacEwan JP; Zhang J; Goldman DP
JAMA Oncol; 2015 May; 1(2):196-202. PubMed ID: 26181023
[TBL] [Abstract][Full Text] [Related]
23. Association Between the Use of Surrogate Measures in Pivotal Trials and Health Technology Assessment Decisions: A Retrospective Analysis of NICE and CADTH Reviews of Cancer Drugs.
Pinto A; Naci H; Neez E; Mossialos E
Value Health; 2020 Mar; 23(3):319-327. PubMed ID: 32197727
[TBL] [Abstract][Full Text] [Related]
24. Public Reimbursement of Prescription Drugs Used For Off-Label Indications in Ontario.
Rawson N; Chhabra A
J Popul Ther Clin Pharmacol; 2018 Sep; 25(2):e23-e30. PubMed ID: 30725540
[TBL] [Abstract][Full Text] [Related]
25. Assessment of the clinical and cost-effectiveness evidence in the reimbursement decisions of new cancer drugs.
Chauca Strand G; Bonander C; Jakobsson N; Johansson N; Svensson M
ESMO Open; 2022 Oct; 7(5):100569. PubMed ID: 36037568
[TBL] [Abstract][Full Text] [Related]
26. Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience.
Lerose R; Musto P; Aieta M; Papa C; Tartarone A
Eur J Clin Pharmacol; 2012 May; 68(5):505-12. PubMed ID: 22166932
[TBL] [Abstract][Full Text] [Related]
27. Off-Label Use of Antipsychotic Agents in Dementia: Evidence for the Revision of the Reimbursement Policy.
Stakišaitis D; Zamarytė-Sakavičienė K; Lesauskaitė V; Jankūnas RJ
Ther Innov Regul Sci; 2019 Jul; 53(4):549-553. PubMed ID: 30200777
[TBL] [Abstract][Full Text] [Related]
28. Off-label use reimbursement.
Cohen J; Wilson A; Faden L
Food Drug Law J; 2009; 64(2):391-403. PubMed ID: 19999289
[TBL] [Abstract][Full Text] [Related]
29. Off-label use of anticancer drugs.
Levêque D
Lancet Oncol; 2008 Nov; 9(11):1102-7. PubMed ID: 19012859
[TBL] [Abstract][Full Text] [Related]
30. Patterns of alternative access: Unpacking the Slovak extraordinary drug reimbursement regime 2012-2016.
Löblová O; Csanádi M; Ozierański P; Kaló Z; King L; McKee M
Health Policy; 2019 Aug; 123(8):713-720. PubMed ID: 31277882
[TBL] [Abstract][Full Text] [Related]
31. [Public financing for off-label use of drugs].
Hammerman A; Lipschitz Y; Pliskin J; Greenberg D
Harefuah; 2011 Feb; 150(2):163-7, 204. PubMed ID: 22164947
[TBL] [Abstract][Full Text] [Related]
32. Real-world Use of and Spending on New Oral Targeted Cancer Drugs in the US, 2011-2018.
Fu M; Naci H; Booth CM; Gyawali B; Cosgrove A; Toh S; Xu Z; Guan X; Ross-Degnan D; Wagner AK
JAMA Intern Med; 2021 Dec; 181(12):1596-1604. PubMed ID: 34661604
[TBL] [Abstract][Full Text] [Related]
33. Characteristics and survival of patients with cancer with intended off-label use-a cohort study.
Schmitt AM; Walter M; Herbrand AK; Jörger M; Moffa G; Novak U; Hemkens L; Kasenda B
BMJ Open; 2022 May; 12(5):e060453. PubMed ID: 35613810
[TBL] [Abstract][Full Text] [Related]
34. Association of Launch Price and Clinical Value With Reimbursement Decisions for Anticancer Drugs in China.
Zhou J; Lu H; Pan J
Int J Health Policy Manag; 2024 Mar; ():. PubMed ID: 38618837
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials.
Mushti SL; Mulkey F; Sridhara R
Clin Cancer Res; 2018 May; 24(10):2268-2275. PubMed ID: 29326281
[No Abstract] [Full Text] [Related]
36. Association of Quality-of-Life Outcomes in Cancer Drug Trials With Survival Outcomes and Drug Class.
Samuel JN; Booth CM; Eisenhauer E; Brundage M; Berry SR; Gyawali B
JAMA Oncol; 2022 Jun; 8(6):879-886. PubMed ID: 35482347
[TBL] [Abstract][Full Text] [Related]
37. A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors: A Meta-analysis of Correlation and Differences in Effect Sizes.
Gyawali B; Hey SP; Kesselheim AS
JAMA Netw Open; 2018 Jun; 1(2):e180416. PubMed ID: 30646078
[TBL] [Abstract][Full Text] [Related]
38. Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020.
Zhang Y; Naci H; Wagner AK; Xu Z; Yang Y; Zhu J; Ji J; Shi L; Guan X
JAMA Netw Open; 2022 Aug; 5(8):e2225973. PubMed ID: 35947385
[TBL] [Abstract][Full Text] [Related]
39. Examining the association between oncology drug clinical benefit and the time to public reimbursement.
Thomson S; Everest L; Witzke N; Jiao T; Delos Santos S; Nguyen V; Cheung MC; Chan KKW
Cancer Med; 2022 Jan; 11(2):380-391. PubMed ID: 34850587
[TBL] [Abstract][Full Text] [Related]
40. The impact of expanding health insurance coverage for anti-cancer drugs on cancer survival in Korea.
Cho DY; Park J; Kim DS
Cancer Med; 2021 Jul; 10(13):4555-4563. PubMed ID: 34145980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
